News
ENTA
13.23
-5.50%
-0.77
Enanta Pharmaceuticals Insider Sellers Vindicated After 15% Drop
Enanta Pharmaceuticals, Inc. Insiders sold US$325k worth of shares in the last year. The company's market cap plunged by US$54m last week. In the past year, Enanta pharmaceuticals insiders have sold an average of US$9.40 per share. The biggest single sale was by Terry Vance for US$139k. Enanta Pharmaceutical's insiders own about 6.2% of the company. But the company doesn't have any insider purchases over the last 12 months. You can see the insider transactions at Enanta pharmaceuticals in the last 12 months .
Simply Wall St · 1d ago
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
Data from the company’s SPRINT study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 in Barcelona, Spain. The poster presentation includes analyses from the double-blind, placebo-controlled Phase 2 clinical trial. Enanta is a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology.
Barchart · 2d ago
Weekly Report: what happened at ENTA last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at ENTA last week (0401-0405)?
Weekly Report · 04/08 09:28
Weekly Report: what happened at ENTA last week (0325-0329)?
Weekly Report · 04/01 09:27
Weekly Report: what happened at ENTA last week (0318-0322)?
Weekly Report · 03/25 09:28
Inventiva Phase 2 study for MASH drug meets primary endpoint
Inventiva Phase 2 study for MASH drug meets primary endpoint. Inventiva's drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes. Last week, Madrigal drug Rezdiffra became the first FDA-approved treatment for the liver disorder.
Seeking Alpha · 03/18 21:45
Weekly Report: what happened at ENTA last week (0311-0315)?
Weekly Report · 03/18 09:28
Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades
FDA approves Madrigal Pharmaceuticals' new drug for nonalcoholic steatohepatitis. Rezdiffra is the first U.S.-approved therapy for NASH. B. Riley upgrades the company's stock to Neutral from Sell. The company's shares are up 26% in the premarket.
Seeking Alpha · 03/15 12:19
Madrigal granted FDA approval for NASH therapy
Madrigal Pharmaceuticals' lead asset resmetirom is the first U.S.-approved therapy for a liver condition called nonalcoholic steatohepatitis. The drug will be indicated with diet and exercise for NASH with moderate to advanced liver fibrosis. Madrigal granted FDA approval for NASh therapy for March 14, 2024.
Seeking Alpha · 03/14 19:45
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy. Companies focused on developing drugs for a liver disease called nonalcoholic steatohepatitis are among the notable decliners. Madrigal Pharmaceuticals' lead asset, resmetirom, is targeted at NASH.
Seeking Alpha · 03/14 14:42
Liver drug developers outperform as U.S. awaits first NASH drug
Liver drug developers outperform as U.S. Awaits first NASH drug approval. Madrigal Pharmaceuticals awaits FDA clearance for its lead asset resmetirom. The company's shares have soared 16% this year, outperforming the biopharma industry.
Seeking Alpha · 03/13 17:29
Enanta Pharmaceuticals Shareholders Affirm Management Direction
TipRanks · 03/12 20:13
Weekly Report: what happened at ENTA last week (0304-0308)?
Weekly Report · 03/11 09:27
Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
Enanta Pharmaceuticals, Inc. Is a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology. The company will participate in a fireside chat at Leerink Partners Global Biopharma Conference on March 13, 2024. A live webcast of the event will be available at www.enanta.com.
Barchart · 03/06 06:00
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Enanta Pharmaceuticals, Inc. Shares have gained 27% in the last 30 days. The company's price-to-sales ratio of 4.5x is lower than the rest of the Biotechs industry. However, the company's revenue growth has been going backwards recently. Its outlook for shrinking revenue is contributing to its low P/S ratio.
Simply Wall St · 03/05 10:01
Weekly Report: what happened at ENTA last week (0226-0301)?
Weekly Report · 03/04 09:28
Weekly Report: what happened at ENTA last week (0219-0223)?
Weekly Report · 02/26 09:30
Weekly Report: what happened at ENTA last week (0212-0216)?
Weekly Report · 02/19 09:31
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) just released its latest quarterly report. Revenues fell 18% short of analyst estimates at US$18m. Statutory losses were 29% bigger than what the analysts expected. The analysts also increased their loss per share estimates for the company for next year. However, forecasts imply the company will perform worse than the wider industry.
Simply Wall St · 02/12 11:12
More
Webull provides a variety of real-time ENTA stock news. You can receive the latest news about Enanta Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).